CYTOTOXIC CHEMOTHERAPY FOR ADVANCED HORMONE-RESISTANT PROSTATE CANCER
作者： Alan Yagoda , Daniel Petrylak
DOI: 10.1002/1097-0142(19930201)71:3+<1098::AID-CNCR2820711432>3.0.CO;2-G
关键词: Prostate 、 Prostate cancer 、 Hormone-Resistant Prostate Cancer 、 Drug resistance 、 Fluorouracil 、 Oncology 、 Prostate-specific antigen 、 Internal medicine 、 Estramustine 、 Adenocarcinoma 、 Medicine
摘要: Background. Advanced adenocarcinoma of the prostate after hormonal manipulation has been noted to be a relatively chemotherapeutic nonresponsive tumor. Earlier reviews have reported objective responses, that is, complete and partial remissions in 6.5% 3184 patients, current review examines efficacy new agents. Methods. The consists 26 drug trials culled from papers abstracts published between 1987-1991. Results. Results these found similar trend, 8.7% (95% confidence interval, 6.4-9.0%), indicating hormone-resistant still fails respond most cytotoxic agents
sci-hub.se 参考文章(31)
Raghavan D, Non-hormone chemotherapy for prostate cancer: principles of treatment and application to the testing of new drugs. Seminars in Oncology. ,vol. 15, pp. 371- 389 ,(1988)
James N. Atkins, Hyman B. Muss, Douglas Case, Joni Brockschmidt, Frederick M. Schnell, Mark OʼRourke, Thomas H. Grote, John H. West, Susan Anthony, Valerie Stanley, High-dose 24-hour infusion of 5-fluorouracil in metastatic prostate cancer. A phase II trial of the Piedmont Oncology Association. American Journal of Clinical Oncology. ,vol. 14, pp. 526- 529 ,(1991) , 10.1097/00000421-199112000-00012
H. I. Scher, A. Yagoda, Clinical Trials in Prostatic Cancer: Methodology and Controversies Springer London. pp. 197- 219 ,(1987) , 10.1007/978-1-4471-1398-0_13
Barry S. Stein, Surya Vangore, Robert O. Petersen, Immunoperoxidase localization of prostatic antigens. Comparison of primary and metastatic sites. Urology. ,vol. 24, pp. 146- 152 ,(1984) , 10.1016/0090-4295(84)90416-3
Kenneth D. Tew, Beryl Hartley-Asp, Cytotoxic properties of estramustine unrelated to alkylating and steroid constituents Urology. ,vol. 23, pp. 28- 33 ,(1984) , 10.1016/S0090-4295(84)80094-1
Robert B. Sklaroff, Alan Yagoda, Cis-diamminedichloride platinum II (DDP) in the treatment of penile carcinoma Cancer. ,vol. 44, pp. 1563- 1565 ,(1979) , 10.1002/1097-0142(197911)44:5<1563::AID-CNCR2820440503>3.0.CO;2-S
E.W. Pommerenke, H. Osswald, E.W. Hahn, M. Volm, Activity of various amphiphilic agents in reversing multidrug resistance of L 1210 cells. Cancer Letters. ,vol. 55, pp. 17- 23 ,(1990) , 10.1016/0304-3835(90)90060-B
NicholasJ. Vogelzang, VictorJ. Lanzotti, Betty Muntean, RichardR. Blough, Bisantrene in advanced, hormone-resistant carcinoma of the prostate: an Illinois Cancer Council phase II study. Investigational New Drugs. ,vol. 8, pp. 313- 315 ,(1990) , 10.1007/BF00171845
Alan Yagoda, Robin C. Watson, Ronald B. Natale, Winston Barzell, Pramod Sogani, Harry Grabstald, Willet F. Whitmore, A critical analysis of response criteria in patients with prostatic cancer treated with CIS-diamminedichloride platinum II Cancer. ,vol. 44, pp. 1553- 1562 ,(1979) , 10.1002/1097-0142(197911)44:5<1553::AID-CNCR2820440502>3.0.CO;2-W
M E Stearns, M Wang, K D Tew, L I Binder, Estramustine binds a MAP-1-like protein to inhibit microtubule assembly in vitro and disrupt microtubule organization in DU 145 cells Journal of Cell Biology. ,vol. 107, pp. 2647- 2656 ,(1988) , 10.1083/JCB.107.6.2647